Jim Cramer recently discussed Johnson & Johnson (NYSE:JNJ), praising its cancer drug portfolio and business spinoff strategies. The company’s shares have gained 47.8% over the past year. Bernstein raised the share price target to $208, citing clearer visibility into macroeconomic uncertainties. Mar Vista U.S. Quality Strategy also highlighted JNJ’s strong performance in Q4 2025, driven by robust financial results and accelerating growth in pharmaceutical and medical technology segments. Management expects 5-7% revenue growth through 2030.

Read more at Yahoo Finance: Jim Cramer Just Can’t Stop Praising Johnson & Johnson (JNJ)